Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Consensus "Moderate Buy": Eleven analysts cover Immunome with a consensus Moderate Buy (10 buys, 1 sell) and an average 12‑month target of $33.45, with individual targets up to $40.
• Stock and results: Shares opened at $20.02 (market cap ~$2.27B) and trade in a 52‑week range of $5.15–$27.65; the company missed quarterly EPS (reported <$strong>-$0.75 vs. -$0.65 expected) and analysts forecast -2.21 EPS for the year, reflecting sizable negative margins.
• Insider and institutional moves: Director Isaac Barchas sold 383,200 shares (~$8.33M) while CEO Clay Siegall bought 4,729 shares; insiders own 7.69% and institutional ownership is 44.58% after large additions from T. Rowe Price, Vanguard, Primecap, State Street and JPMorgan.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $33.4545.

A number of analysts have recently issued reports on IMNM shares. Leerink Partners set a $40.00 price target on shares of Immunome in a research report on Monday, December 15th. Wedbush reaffirmed an "outperform" rating and set a $31.00 price objective on shares of Immunome in a research report on Thursday, January 15th. Craig Hallum upped their price objective on shares of Immunome from $33.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Stephens decreased their target price on shares of Immunome from $33.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, March 4th. Finally, Lake Street Capital boosted their price target on shares of Immunome from $22.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, December 16th.

Immunome Trading Down 3.9%

Shares of IMNM stock opened at $20.02 on Friday. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -8.27 and a beta of 2.12. Immunome has a 1-year low of $5.15 and a 1-year high of $27.65. The stock's fifty day simple moving average is $22.76 and its 200-day simple moving average is $18.44.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. On average, sell-side analysts predict that Immunome will post -2.21 EPS for the current year.

Insiders Place Their Bets

In other news, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares in the company, valued at $44,157,874.94. The trade was a 15.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall purchased 4,729 shares of the stock in a transaction that occurred on Tuesday, December 30th. The stock was purchased at an average cost of $21.15 per share, with a total value of $100,018.35. Following the purchase, the chief executive officer owned 665,254 shares in the company, valued at $14,070,122.10. This represents a 0.72% increase in their position. The SEC filing for this purchase provides additional information. 7.69% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its position in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company's stock worth $288,305,000 after acquiring an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company's stock valued at $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA raised its holdings in shares of Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company's stock valued at $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. State Street Corp lifted its stake in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company's stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company's stock worth $61,341,000 after purchasing an additional 2,823,144 shares in the last quarter. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.